Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Department of Pharmacology and Toxicology staff profiles

Zohaib Rana

PositionPhD Student
DepartmentDepartment of Pharmacology and Toxicology

Publications

Shakil, M. S., Parveen, S., Rana, Z., Walsh, F., Movassaghi, S., Söhnel, T., Azam, M., … Rosengren, R. J., & Hartinger, C. G. (2021). High antiproliferative activity of hydroxythiopyridones over hydroxypyridones and their organoruthenium complexes. Biomedicines, 9, 123. doi: 10.3390/biomedicines9020123

Rana, Z., Tyndall, J. D. A., Hanif, M., Hartinger, C. G., & Rosengren, R. J. (2021). Cytostatic action of novel histone deacetylase inhibitors in androgen receptor-null prostate cancer cells. Pharmaceuticals, 14, 103. doi: 10.3390/ph14020103

Hanif, M., Arshad, J., Astin, J. W., Rana, Z., Zafari, A., Movassaghi, S., … Rosengren, R. J., … Hartinger, C. G. (2020). A multitargeted approach: Organorhodium anticancer agent based on vorinostat as a potent histone deacetylase inhibitor. Angewandte Chemie International Edition, 59, 14609-14614. doi: 10.1002/anie.202005758

Rana, Z., Diermeier, S., Hanif, M., & Rosengren, R. J. (2020). Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines, 8(2), 22. doi: 10.3390/biomedicines8020022

Journal - Research Article

Shakil, M. S., Parveen, S., Rana, Z., Walsh, F., Movassaghi, S., Söhnel, T., Azam, M., … Rosengren, R. J., & Hartinger, C. G. (2021). High antiproliferative activity of hydroxythiopyridones over hydroxypyridones and their organoruthenium complexes. Biomedicines, 9, 123. doi: 10.3390/biomedicines9020123

Rana, Z., Tyndall, J. D. A., Hanif, M., Hartinger, C. G., & Rosengren, R. J. (2021). Cytostatic action of novel histone deacetylase inhibitors in androgen receptor-null prostate cancer cells. Pharmaceuticals, 14, 103. doi: 10.3390/ph14020103

Hanif, M., Arshad, J., Astin, J. W., Rana, Z., Zafari, A., Movassaghi, S., … Rosengren, R. J., … Hartinger, C. G. (2020). A multitargeted approach: Organorhodium anticancer agent based on vorinostat as a potent histone deacetylase inhibitor. Angewandte Chemie International Edition, 59, 14609-14614. doi: 10.1002/anie.202005758

^ Top of page

Journal - Research Other

Rana, Z., Diermeier, S., Hanif, M., & Rosengren, R. J. (2020). Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines, 8(2), 22. doi: 10.3390/biomedicines8020022

More publications...